Patents by Inventor Zaki I. BASSEM

Zaki I. BASSEM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200282054
    Abstract: Disclosed is a method for increasing susceptibility of cancer cells to ionizing radiation by delivering to the cells a radiosensitizing agent that has one of the following properties: it perturbs the process of chromosome segregation thereby increasing chromosome missegregation; or (b) it is an inhibitor of an agent that promotes faithful chromosome segregation induces numeric chromosome instability in said cells and this instability is induced substantially simultaneously with or closely prior to or closely after irradiating the cells. Examples of such radiosensitizing agent include inhibitors of one or more of the following: Kif2b, MCAK, MPS1, Eg5/Kinesin-5 5, Polo-like kinase 4, MCAK, Bub1 and Hec1. Such agents specifically target proteins involved in maintaining or promoting faithful chromosome segregation.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 10, 2020
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Samuel F. BAKHOUM, Zaki I. BASSEM, Duane A. COMPTON
  • Publication number: 20180008709
    Abstract: Disclosed is a method for increasing susceptibility of cancer cells to ionizing radiation by delivering to the cells a radiosensitizing agent that has one of the following properties: (a) it perturbs the process of chromosome segregation thereby increasing chromosome missegregation; or (b) it is an inhibitor of an agent that promotes faithful chromosome segregation induces numeric chromosome instability in said cells and this instability is induced substantially simultaneously with or closely prior to or closely after irradiating the cells. Examples of such radiosensitizing agent include inhibitors of one or more of the following: Kif2b, MCAK, MPS1, Eg5/Kinesin-5 5, Polo-like kinase 4, MCAK, Bub1 and Hec1. Such agents specifically target proteins involved in maintaining or promoting faithful chromosome segregation.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 11, 2018
    Applicants: Memorial Sloan-Kettering Cancer Center, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Samuel F. BAKHOUM, Zaki I. BASSEM, Duane A. COMPTON